Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kathy Mngadi"'
Autor:
Zainab Waggie, Modulakgotla Sebe, Richard E. Chaisson, Katherine Fielding, Gavin J. Churchyard, Kathy Mngadi, Dinis Nguenha, Alison D. Grant, Vicky Cárdenas, Alberto L. García-Basteiro, Whip Tb Study Team, Getnet Yimer, Frank Cobelens, Violet N. Chihota, Susan van den Hof, Shu-Hua Wang, Salome Charalambous, LeeAnne Masilela, Neil A. Martinson, William Brumskine
Publikováno v:
Annals of internal medicine. 174(10)
Background Tuberculosis preventive therapy for persons with HIV infection is effective, but its durability is uncertain. Objective To compare treatment completion rates of weekly isoniazid-rifapentine for 3 months versus daily isoniazid for 6 months
Autor:
Larissa M. Villela, Stephen R. Walsh, Martin R. Gaudinski, John Mascola, Alice Sehurutshi, Javier Valencia, Robert De La Grecca, Myron S. Cohen, Nyaradzo Mgodi, Margarira M. Gomez Lorenzo, Srilatha Edupuganti, Kathy Mngadi, David N. Barnes, Julie Ledgerwood, Simbarashe Takuva, Corey Lawrence, Philip Andrew, Erika Rudnicki, Logashvari Naidoo, Michal Juraska, Carissa Karg, Shelly Karuna, Maija Anderson, Catherine Orrell, John Hural, April K. Randhawa
Publikováno v:
SSRN Electronic Journal.
Background: The AMP studies (HVTN 703/HPTN 081 and HVTN 704/HPTN 085) are two harmonized Phase 2b randomized controlled trials to assess HIV prevention efficacy and safety of intravenous (IV) infusion of anti-gp120 broadly neutralizing monoclonal ant
Autor:
Peter A. Newman, Douglas Wassenaar, Graham Lindegger, Catherine Slack, Abigail Wilkinson, Linda-Gail Bekker, Philippa Kerr, Kathy Mngadi, Siyabonga Thabethe
Publikováno v:
Journal of Empirical Research on Human Research Ethics
Trust is a key element of high-quality stakeholder relations, which are themselves essential for the success of HIV vaccine trials. Where trust is absent, community stakeholders might not volunteer to become involved in key trial activities, and pote
Autor:
Mo Weijtens, Lauren Peter, Glenda Gray, Katleen Callewaert, Erica N. Borducchi, David C. Montefiori, Thomas B. Campbell, Frank Tomaka, Kathy Mngadi, Fatima Laher, Joseph P. Nkolola, David Jetton, Jenny Hendriks, Roland Zahn, Frances Priddy, Edith Swann, Juliet Mpendo, Sorachai Nitayapan, Karin Feddes-de Boer, Wenjun Li, Stephan Bart, Erica Lazarus, Abishek Chandrashekar, Jennifer Johnson, Frank Wegmann, Steven Nijs, Lindsey R. Baden, Merlin L. Robb, Nigel Garrett, Ludo Lavreys, Galit Alter, Dan H. Barouch, Etienne Karita, Hanneke Schuitemaker, Daniel J. Stieh, Georgia D. Tomaras, Nicole Frahm, M. Juliana McElrath, Danielle van Manen, Zelda Euler, Gregg Lucksinger, Lorenz Scheppler, Hannah Kibuuka, Robert Feldman, Raphaele Roten, Maria G. Pau, Kathryn E. Stephenson, Caroline Borremans, Nelson L. Michael, Punnee Pitisuttithum, Jessica Vreugdenhil, Jeroen Tolboom, Jerald C. Sadoff, Kundai Chinyenze, Bette T. Korber, Julia Hutter
Publikováno v:
Lancet, 392(10143), 232-243. Elsevier Limited
Summary Background More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been the lack of direct comparability between clinical trials and p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6169a5479eb278fd28c754f353bca4e7
https://pure.amc.nl/en/publications/evaluation-of-a-mosaic-hiv1-vaccine-in-a-multicentre-randomised-doubleblind-placebocontrolled-phase-12a-clinical-trial-approach-and-in-rhesus-monkeys-nhp-1319(234e01f2-b4e8-4e15-ba68-ebe28532f079).html
https://pure.amc.nl/en/publications/evaluation-of-a-mosaic-hiv1-vaccine-in-a-multicentre-randomised-doubleblind-placebocontrolled-phase-12a-clinical-trial-approach-and-in-rhesus-monkeys-nhp-1319(234e01f2-b4e8-4e15-ba68-ebe28532f079).html